Physician profile
Steven Clark Block
NPI 1962458075
$2,322.13
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $954 · 2023: $495 · 2024: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.00 | 2021-2024 | Rinvoq, Mavyret, Skyrizi |
| Nestle Healthcare Nutrition INC. | $271.69 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $235.28 | 2021-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $234.99 | 2021-2023 | Entyvio, Gattex |
| Qol Medical, LLC | $128.09 | 2022-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $112.37 | 2021-2023 | Stelara, Simponi Aria, Remicade |
| Merck Sharp & Dohme LLC | $81.80 | 2022-2024 | Dificid |
| Daiichi Sankyo INC. | $80.06 | 2021-2024 | Injectafer |
| Amgen INC. | $77.67 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $66.21 | 2024 | Bylvay, Iqirvo |
| Celgene Corporation | $49.62 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.92 | 2021 | |
| Boston Scientific Corporation | $43.40 | 2022 | |
| Vivus LLC | $31.91 | 2023 | Qsymia |
| Fresenius Kabi USA, LLC | $30.28 | 2024 | Smoflipid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.27 | 2023 | Renflexis |
| Pfizer INC. | $19.78 | 2024 | |
| Ferring Pharmaceuticals INC. | $18.17 | 2021 | |
| Aimmune Therapeutics, INC. | $16.94 | 2024 | |
| Horizon Therapeutics Plc | $15.45 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.27 | 2024 | Dupixent |
| Echosens North America, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.